Analyst Consensus (1 calls)
| Stock | Brokerage | Call ↕ | Target | CMP | Upside ↕ |
|---|---|---|---|---|---|
| Goldman Sachs | REDUCE | — | — | — |
Dr. Reddy's Laboratories [DRREDDY] has reportedly delivered an impressive monthly performance, signaling positive momentum for the pharmaceutical major amidst a dynamic market.
Dr. Reddy's Laboratories [DRREDDY] shares saw a notable decline today following a downgrade from Goldman Sachs and cautious remarks from Citigroup, citing limited growth visibility and pipeline concerns.
On April 23, Dr. Reddy's Laboratories [DRREDDY] and three other Nifty500 stocks exhibited a bullish RSI upswing, signaling strengthening momentum and potential short-term buying opportunities.
The pharmaceutical sector defied broader market weakness on Thursday, with Dr. Reddy's Laboratories [DRREDDY] leading gains on anticipation of its Semaglutide drug approval in Canada, highlighting the sector's defensive appeal.
Amidst Nifty's current weakness, market analysts are recommending Dr. Reddy's Laboratories [DRREDDY] and Solar Industries [SOLARINDS] as potential buys, citing bullish signals and strong momentum for gains up to 14%.
Pharma major Dr. Reddy's Laboratories [DRREDDY] is reportedly navigating a challenging phase, prompting investors to closely monitor its performance and sector-specific headwinds.
Monitor Dr. Reddy's Laboratories [DRREDDY] stock performance with live updates and market analysis. Track price movements and understand the pharmaceutical giant's trading patterns.
Dr. Reddy's Laboratories [DRREDDY] concluded trading at ₹1,253.30, reflecting the pharmaceutical giant's current market valuation. Here's what investors should know.